Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 4/20 | 0.75 |
| ▸ | PIM1 | P11309 | 2/20 | 0.75 |
| ▸ | GSK3B | P49841 | 2/20 | 0.75 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.75 |
| ▸ | CLK1 | P49759 | 1/20 | 0.75 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.75 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.75 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384783 | 0.88 | CDC7 (0.72) | CDC7PIM1GSK3BCSNK2A2CLK1 | |
| SCHEMBL385819 | 0.87 | CDC7 (0.82) | CDC7PIM1GSK3BCSNK2A2CLK1 | |
| SCHEMBL386108 | 0.87 | CDC7 (0.82) | CDC7PIM1GSK3BCSNK2A2CLK1 | |
| SCHEMBL19783008 | 0.86 | CXCL12 (0.74) | CDC7PIM1GSK3BCSNK2A2CLK1 | |
| SCHEMBL385553 | 0.86 | CDC7 (0.66) | CDC7PIM1GSK3BCSNK2A2CLK1 | |
| SCHEMBL385492 | 0.86 | CDC7 (0.64) | CDC7PIM1GSK3BCSNK2A2CLK1 | |
| SCHEMBL10165675 | 0.86 | CDC7 (1.00) | CDC7PIM1GSK3BCSNK2A2CLK1 | |
| SCHEMBL385150 | 0.85 | CDC7 (0.68) | CDC7PIM1GSK3BCSNK2A2CLK1 | |
| SCHEMBL12514657 | 0.85 | PIM1 (0.59) | CDC7PIM1GSK3BCSNK2A2CLK1 | |
| SCHEMBL385067 | 0.85 | PIM1 (0.59) | CDC7PIM1GSK3BCSNK2A2CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | claimed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | claimed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | claimed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2007048065-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | CSNK2A1, CSNK1A1, CSNK2A2 | CDC7 536/4885PIM1 429/4885GSK3B 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.